Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
View/Download PDF

Translate this page into:

Original Article
154 (
6
); 843-848
doi:
10.4103/ijmr.IJMR_684_19

High soluble interleukin-2 receptor values in Indian paediatric & adult controls – Need for population-specific threshold in the diagnosis of haemophagocytic lymphohistiocytosis

Department of Research, Sir Ganga Ram Hospital, New Delhi, India
Department of Pediatric Hematology Oncology & Bone Marrow Transplantation, Sir Ganga Ram Hospital, New Delhi, India
Department of Pediatric Surgery, Sir Ganga Ram Hospital, New Delhi, India
Department of Anesthesiology, Sir Ganga Ram Hospital, New Delhi, India
Department of Pediatric Intensive Care, Sir Ganga Ram Hospital, New Delhi, India

For correspondence: Dr Anupam Sachdeva, Department of Pediatrics, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110 060, India e-mail: anupamace@yahoo.co.in

Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Background & objectives:

Elevated soluble interleukin-2 receptor (sIL2R) is a diagnostic criterion for haemophagocytic lymphohistiocytosis (HLH). International guidelines propose a 2400 U/ml cut-off or individual laboratory-defined cut-off. However, sIL2R normal values are so far not known in Indians. So, this study was undertaken to measure sIL2R in healthy children and adults to establish age-related reference values.

Methods:

Healthy controls and cases (participants with persistent fever, organomegaly, cytopenias and biochemical markers of HLH) were prospectively enrolled. Serum sIL2R was measured by double-sandwich enzyme immunoassay in a standardization batch to determine the optimum cut-off value using receiver operator characteristic curve and was subsequently validated.

Results:

One hundred and forty six age- and sex-matched children (80 controls and 66 suspected HLH cases) and 55 adults (49 controls and 6 suspected HLH cases) were prospectively enrolled. The optimal sIL2R cut-off ≥23 ng/ml was defined as raised sIL2R in the standardization batch. No controls had sIL2R ≥23 ng/ml in the validation batch. In healthy controls, median sIL2R (interquartile range) decreased with increasing age from 9.0 ng/ml (6.6-13.4) below five years of age to 3.2 ng/ml (2.8-5.1) in adults. Proposed upper limit of normal value for sIL2R is 17.4 ng/ml in less than five year, 12.2 ng/ml in 5-9 yr, 6.7 ng/ml in 10-17 yr and 5.2 ng/ml in ≥18 yr. sIL2R accuracy to diagnose HLH marginally improved with age-appropriate cut-off.

Interpretation & conclusions:

Paediatric controls in India showed higher sIL2R levels than most studies conducted in other countries, except for some reports in Chinese and Russian populations. Age-appropriate reference values of sIL2R in a specific population may be considered to determine elevated sIL2R as a marker of HLH.

Keywords

Enzyme-linked immunosorbent assay
haemophagocytic lymphohistiocytosis
India
reference values
soluble CD25
soluble interleukin-2 receptor

One of the increasingly frequent causes of fever, organomegaly and cytopenia in paediatric and adult patients is haemophagocytic lymphohistiocytosis (HLH)1. HLH is a cellular immune dysregulation resulting from underlying genetic defects or triggered by severe infection [infection-associated haemophagocytic syndrome (IAHS)], malignancy [malignancy-associated haemophagocytic syndrome (MAHS)] or rheumatological condition (macrophage activation syndrome)1.

HLH 2004 diagnostic criteria2 are either the presence of a familial disease or a known genetic defect or the presence of five out of eight diagnostic criteria, which include fever, splenomegaly, bicytopenia, hyperferritinaemia, hypertriglyceridaemia and/or hypofibrinogenaemia, haemophagocytosis in bone marrow or spleen or lymph nodes, decreased or absent NK cell activity and raised soluble CD25 [soluble interleukin-2 receptor (sIL2R)]. Elevated levels of sIL2R were first documented in HLH in 19893 and are widely found in HLH. Induced by uncontrolled and ineffective immune activation by lymphocytes, sIL2R is a laboratory indicator of in vivo immune system activation. The suggested threshold for raised sIL2R is either 2400 U/ml or above normal limits for age as per laboratory-specific threshold24. There is no clearly defined relation between ng/ml and U/ml concentrations, and both units have been used in published reports, but mostly U/ml5. sIL2R levels in healthy individuals are known to be higher in children than in adults and decrease with increasing age56. However, this assay is not commonly available in India. To the best of our knowledge, age-wise sIL2R serum concentrations in healthy Indian subjects are not known, so the dilemma is that, to which levels the diseased subjects should be compared. Thus, a prospective study was conducted to establish the normal range of sIL2R in the serum of North Indian children and young adults and the age-specific cut-off value for elevated sIL2R as a marker of HLH.

Material & Methods

A descriptive/cross-sectional study was conducted at Sir Ganga Ram Hospital, a tertiary care hospital in New Delhi, from January 2014 to March 2018 after obtaining approval from the Institutional Ethics Committee.

Selection of study participants: Children and adults with persistent fever, organomegaly, bicytopenias and biochemical markers of HLH were labelled as HLH cases as per HLH 2004 criteria2 and sampled prior to initiation of immunosuppressive therapy. Healthy age-matched controls included children undergoing elective surgery (circumcision and correction of congenital anomalies) or HLA typing and children consulting for minor non-febrile illness (iron deficiency anaemia, immune thrombocytopenia and acute gastritis) as well as adult blood donors.

Sample collection and processing: After obtaining written consent from adults/guardians or child’s assent as applicable, blood samples collected in plain vials were centrifuged and serum was stored at −20°C until testing. Both plasma and serum samples were compared while standardizing the assay. Serum samples showed lower within-assay variation, hence, serum was the sample type chosen for the study. A double-sandwich enzyme-linked immunosorbent assay (Human sIL-2R Platinum ELISA, eBioscience, San Diego, CA, USA) was used to measure sIL2R, running all standards (serial dilutions from 20 to 0.625 ng/mL) and test samples in duplicates. Optical density was analyzed with Infinite 200 PRO ELISA plate reader (Tecan, Switzerland). As no predefined equivalence between nanogram and international units was given in the kit, and due to varied conversion methods found in the literature, receiver operating characteristic (ROC) curves were used in a first batch of cases and controls (standardization batch) to determine the optimal cut-off value of sIL2R distinguishing cases from controls (area under the curve: 0.954). This cut-off was further tested in a validation group of cases and controls. Upper limit of normal (ULN) value was calculated as median+2 standard deviations (SDs).

Statistical analysis: Statistical analysis was conducted using SPSS Statistics for Windows, Version 17.0 (SPSS Inc. IBM Corp. Chicago, IL, USA). Age-wise distribution of sIL2R in healthy controls was assessed. Pearson’s Chi-square or Fisher’s exact test was used to compare categorical variables. Normal range in each age group was defined as mean±2 SDs. ULN value was defined as median sIL2R + 2 SDs in each age group. Mann–Whitney U test was used to compare sIL2R levels in various groups, after confirming non-normality using Shapiro–Wilk test. Continuous variables were compared using Spearman’s rank correlation.

Results

A total of 207 individuals were prospectively enrolled: 146 children (80 controls and 66 cases) and 55 adults (49 controls and 6 cases). Cases and controls had similar age/sex distribution (Table I). The standardization batch included 12 cases and 18 controls. ROC curve identified the optimal sIL2R cut-off to segregate cases from controls as 23 ng/ml. This cut-off in the validation batch showed sIL2R ≥23 ng/ml in 41 (68.3%) out of 60 cases of suspected HLH and none of the 111 controls (P<0.001). Between-assay and within-assay variation coefficients were 12.4 and 6.3 per cent, respectively.

Table I Demographics and serum soluble interleukin-2 receptor level in controls and in haemophagocytic lymphohistiocytosis (HLH) cases (n=207)
Total (n=201) Controls (n=129) HLH cases (n=72)
Children (n=80) Adults (n=49) Children (n=66) Adults (n=6)
Demographics
Standardization batch n=30 18 0 12 0
Validation batch n=171 62 49 54 6
Sex male/female 139/62 54/26a 39/10b 42/24a 4/2b
Mean age±SD in years (range) 6.4±4.6a (0.2-17) 34.4±8.8b (20-52) 6.1±5.1a (0.1-17) 38.0±14.8b (18-58)
Median sIL2R (IQR) (ng/ml) n=201 6.7c (4.6-9.4) 3.2c (2.8-5.1) 35.3d (21.2-52.3) 25.7d (8.5-30.8)
Standardization batch n=30 9.0e, f (5.8-13.8) 36.2e (28.1-45.0)
Validation batch n=171 6.3e, f (4.3-8.5) 3.2g (2.8-.1) 34.1e (19.9-53.8) 25.7g (8.5-30.8)

aP>0.05 when comparing demographics in paediatric controls and cases; bP>0.05 when comparing demographics in adult controls and cases; cP<0.001 when comparing sIL2R in paediatric and adult controls; dP=0.15 when comparing paediatric and adult cases; eP<0.001 when comparing sIL2R in paediatric controls and cases; fThe age of paediatric controls was lower in the standardization group than in the validation group: mean age±SD 5.7±4.0, range (1-13) vs. 6.6±4.7 (0.2-17), P=0.56, gP=0.002 when comparing sIL2R in adult controls and cases. sIL2R, soluble interleukin-2 receptor; IQR, interquartile range; SD, standard deviation

Soluble interleukin-2 receptor in healthy controls: In healthy controls, sIL2R showed a significant inverse relationship with age (r=−0.7, P<0.001; Table II), as reported previously56. Median sIL2R levels were significantly higher in paediatric controls than in adult controls (Table I). Our paediatric control selection included 39 healthy children and 41 children with non-febrile minor illnesses. Both control groups were compared in every age group, and sIL2R levels showed no significant difference (Supplementary Table). ULN values are given in Table II.

Table II Serum soluble interleukin-2 receptor in controls and proposed upper limit of normal for age (n=129)
Age group (yr) n Mean±SD (ng/ml) Median IQR Minimum-maximum Normal range ULN (ng/mL) sIL2R >ULN
<5 36 9.9±4.4 9.0 6.6-13.4 3.1-20.0 1.1-18.7 17.8 3 (8.3)
5-9 22 6.7±3.0 6.2 4.4-8.1 2.2-14.4 0.6-12.8 12.2 2 (9.1)
10-17 22 5.0±1.0 4.7 3.8-6.0 2.1-8.9 1.3-8.6 6.7 4 (18.2)
≥18 49 3.8±1.0 3.2 2.9-5.1 1.7-7.3 0.9-6.7 5.2 11 (22.4)
Total 129 6.2±3.8 5.2 3.2-7.9 1.7-20.0

Normal range: mean±2SDs. ULN: Median+2SDs. ULN, upper limit of normal; SD, standard deviation; IQR: interquartile range; sIL2R, soluble interleukin-2 receptor

Supplementary Table Soluble interleukin-2 receptor in two subgroups of controls (n=129)
Age group (yr) Healthy controls Minor illness P#
n Mean±SD (ng/ml) Median (IQR) n Mean±SD (ng/ml) Median (IQR)
<5 17 9.8±3.9 10.2 (7.3-13.1) 19 10.0±4.9 8.1 (6.5-14.9) 0.85
5-9 8 6.2±3.6 5.4 (4.3-6.9) 14 6.9±2.8 7.3 (4.7-8.7) 0.27
10-17 22 6.6±1.5 4.6 (3.5-5.6) 8 5.6±2.3 4.9 (3.9-8.1) 0.44
≥18 49 3.8±1.4 3.2 (2.7-5.1) 0

#Mann–Whitney U test comparing both subgroups of controls. IQR, interquartile range; SD, standard deviation

Soluble interleukin-2 receptor in cases with haemophagocytic lymphohistiocytosis: Children and adults with suspected/confirmed HLH included 18 cases of primary HLH (3 with PRF-1 deficiency and 15 with positive family history), 27 cases of IAHS (EBV – 7, dengue – 5, enteric fever – 3, tuberculosis – 2 and 10 cases of other viruses or bacteria), 10 cases of macrophage activation syndrome (6 – juvenile idiopathic arthritis, 3 – systemic lupus erythematosus and 1 – Kikuchi’s disease), 5 cases of MAHS (4 – lymphomas and 1 – Wilms’ tumour) and 12 cases of unclassified HLH. Clinical symptoms and laboratory findings in patients with HLH are shown in Table III.

Table III Clinical characteristics of patients with haemophagocytic lymphohistiocytosis (n=72)
Characteristics n (%)
Fever 72 (100)
Splenomegaly 52 (72.2)
Bicytopeniaa 66 (91.7)
Ferritin >500 ng/ml 72 (100)
Triglycerides >265 mg/dl (n=66) 33 (50)
Fibrinogen <1.5 g/dl (n=70) 41 (58.6)
Bone marrow haemophagocytosis 63 (92.6)
CNS involvement 5 (6.9)
Hyponatraemia (n=69) 22 (31.9)
30-day mortality (n=70)b 23 (32.8)
Overall mortality 41 (58.6)
Biochemical parameters Median Range
Haemoglobin (g/dl) 8.6 5.5-11.6
Neutrophils (per ml) 1940 0-22,000
Platelets (per ml) 39,000 8000-175,000
Ferritin (ng/ml) 7990 666-98,227
SGOT (n=62) 188 19-9962
SGPT (n=67) 99 16-183
Albumin (n=30) 2.1 1-3.7

aHb <9 g/dl (<10 in infants), platelets <100,000/ml, neutrophils <1000/ml; bTwo children abandoned treatment and were lost to follow up. Hb, haemoglobin; CNS, central nervous system; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase

As expected, HLH cases had significantly higher sIL2R levels than controls in all age groups (Table IV). The proportion of cases with sIL2R ≥23 ng/ml decreased from 84.4 per cent in children below five years to 50 per cent in adults. When the ULN was used to define elevated sIL2R for age, 86.1 per cent of HLH cases had raised sIL2R.

Table IV Serum soluble interleukin-2 receptor in patients with haemophagocytic lymphohistiocytosis (n=72)
Age group (yr) n Median (ng/ml) IQR Range sIL2R >ULN, n (%)
<5 32 38.8** 29.2-52.6 9.5-130 28 (87.5)
5-9 14 29.9** 14.8-47.8 5.0-83.5 11 (78.6)
10-17 20 27.7** 10.8-51.1 4.7-80.9 18 (90.0)
≥18 6 25.7* 8.5-30.8 2.6-43.4 5 (90.0)
Total 72 33.9** 20.6-49.9 2.6-130 62 (86.1)

P *<0.01, **<0.001, Mann–Whitney U test comparing patients with HLH and controls. All values are in ng/ml

Discussion

At present, no reference values of sIL2R are available from the Indian population. Although there are a few studies on sIL2R in various disease conditions including healthy controls, sIL2R levels vary greatly among the published reports, many of which measure it in U/ml, with varied conversion factors to ng/ml. Decreasing sIL2R levels with increasing age in healthy individuals has been previously reported56.

The normal range of sIL2R in healthy adults in our study agrees with a previous report from Russia, in which 16 adult controls had a median (range) serum sIL2R of 3.3 ng/ml6 (Table V). However, Japanese controls had a lower serum sIL2R in children and in adults with ages similar to our series7. In China, Gao et al8 too reported low levels of sIL2R in children aged 2-3 yr. Two reports used the same manufacturer as the present study, Zhao et al9 described serum sIL2R in Chinese children aged 3-12 yr similar to the present study, while Deveci et al10 reported considerably lower sIL2R than the present study910 (Table V). Thus, both children and adults from India seem to have higher serum sIL2R concentrations than most reports.

Table V Studies reporting soluble interleukin-2 receptor quantitation in healthy controls
Studies Country n Age (yr) Sample sIL2R
Paediatric controls
Gotoh et al7, 1999 Japan 56 5.3±3.8a (1-14) Serum 1.5±0.9 ng/mla
Gao et al8, 2015 China 14 1.6 (1.9-3.3)b Plasma 0.99 (0.8-1.1) ng/mlb
Deveci et al10, 2014 Turkey 38 10.2±3.7a Serum 0.6 (0.1-2.6) ng/mlb
Zhao et al9, 2018 China 64 6.7±1.4a (6-12) Serum 7.3±2.2 ng/mla, c
Present study India 86 6.4±4.6a (0.2-17) Serum 6.7 (4.6-9.4) ng/mlb
7.7±4.1 ng/mld
Adult controls
Gotoh et al7, 1999 Japan 38 37±11a (22-67) Serum 0.7±0.3 ng/mla
Barabanshikova et al6, 2017 Russia 16 56 (50-67)b Serum 3.3 (0.9-5.8) ng/mlb
Present study India 49 34.4±8.8a (20-52) Serum 3.2 (2.8-5.1) ng/mlb
3.8±1.4 ng/mld

aMean±SD; bMedian (range); cThe authors wrongly reported pg/ml, but the kit mentioned measures sIL2R in ng/ml (assay range 0.31-20 ng/mL); dMean±SD is given for comparison with other studies, but data are non-normally distributed

As a proportion of our paediatric cases, the study controls were not strictly healthy and may have had some degree of inflammation, this could have caused higher sIL2R levels; however, the subgroup of controls with minor non-febrile illness and elective surgery had the same levels as children sampled for HLA typing. This is a major limitation of this study.

Another possible reason for higher sIL2R levels in Indian controls may be a high parasitic load, since children living in tropical countries are more prone to gastrointestinal infections and parasitic disease1112. Recently, elevated sIL2R levels was found to correlate with severity of malaria13.

Data from this study will help in interpretation of sIL2R testing in suspected cases with HLH in India. Further studies may demonstrate whether specific cut-offs would help identify HLH in patients with fever, infection or autoimmune disease.

Overall, our study confirms that elevated sIL2R levels is a good marker of HLH. sIL2R levels in healthy subjects are higher in younger children and decrease with increasing age. Normal values should be assessed by the method intended to be used in patients. Determining age-appropriate sIL2R cut-offs is absolutely essential to define increased sIL2R in a specific population.

Acknowledgment

Authors acknowledge Ms Kriti Jain and Ms Rizwana Mirza for their technical help in sample processing.

Financial support & sponsorship: The study was funded by the Department of Research, Sir Ganga Ram Hospital, New Delhi, India.

Conflicts of Interest: None.

References

  1. , , , , , . Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:435-44.
    [Google Scholar]
  2. , , , , , , . HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-31.
    [Google Scholar]
  3. , , , . Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood. 1989;73:2128-32.
    [Google Scholar]
  4. , . The expanding spectrum of hemophagocytic lymphohistiocytosis. Curr Opin Allergy Clin Immunol. 2011;11:512-6.
    [Google Scholar]
  5. , , , , , , . Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96:1241-51.
    [Google Scholar]
  6. , , , , , , . Clinical correlates and prognostic significance of IL-8, sIL-2R, and immunoglobulin-free light chain levels in patients with myelofibrosis. Oncol Res Treat. 2017;40:574-8.
    [Google Scholar]
  7. , , , , , , . Determination of age-related changes in human soluble interleukin 2 receptor in body fluids of normal subjects as a control value against disease states. Clin Chim Acta. 1999;289:89-97.
    [Google Scholar]
  8. , , , , , . Pre-B-cell colony-enhancing factor is markedly elevated in childhood hemophagocytic lymphohistiocytosis. Genet Mol Res. 2015;14:5287-95.
    [Google Scholar]
  9. , , , , , , . Effect of allogeneic blood transfusion on levels of IL-6 and sIL-R2 in peripheral blood of children with acute lymphocytic leukemia. Oncol Lett. 2018;16:849-52.
    [Google Scholar]
  10. , , , , , , . Evaluation of the serum levels of soluble IL-2 receptor and endothelin-1 in children with Crimean-Congo hemorrhagic fever. APMIS. 2014;122:643-7.
    [Google Scholar]
  11. , , , , , , . Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet. 2006;367:1521-32.
    [Google Scholar]
  12. , , , . The intestinal protozoa: emerging impact on global health and development. Curr Opin Gastroenterol. 2015;31:38-44.
    [Google Scholar]
  13. , , , , , , . Soluble markers of neutrophil, T-cell and monocyte activation are associated with disease severity and parasitemia in falciparum malaria. BMC Infect Dis. 2018;18:670.
    [Google Scholar]
Show Sections
Scroll to Top